Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Saronno – page 191

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Saronno at a glance
2 862
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 862 trials in Saronno

Open in trial search

Study of Osimertinib and Chemotherapy for Patients with EGFR Mutation Positive Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study Comparing Selpercatinib with a Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Study Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Eli Lilly & Co.

Anal cancer recurrent

Not recruiting

Study of Retifanlimab, Carboplatin, and Paclitaxel for Patients with Inoperable or Metastatic Anal Canal Squamous Cell Carcinoma Not Treated with Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Neoplasm malignant+2

Not recruiting

Study of TYRA-300 for Patients with Advanced Bladder Cancer and Other Solid Tumors with FGFR3 Gene Changes

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:TYRA-300-B01
  • Sponsor:Tyra Biosciences Inc.

Lupus nephritis+1

Not recruiting

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vemircopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Medica Scientia Innovation Research S.L.

Study of Selinexor, Ifosfamide, Etoposide, and Dexamethasone for Patients with Relapsed or Refractory Peripheral T-cell Lymphomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Etoposide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study of Atidarsagene Autotemcel for Treating Early Onset Metachromatic Leukodystrophy (MLD) in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Orchard Therapeutics (Europe) Limited

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson's Disease Patients with Motor Fluctuations

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Neuroderm Ltd.

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

  • MET deregulation therapy assessment
  • Second-line combination treatments
  • EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

  • Endocrine-responsive breast cancer treatment
  • Ovarian cancer maintenance therapy
  • BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

  • Metastatic renal cancer therapy
  • Atrial fibrillation management
  • Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.